Replies to post #242246 on Biotech Values

[DewDiligence]

Cend's financials have not yet been disclosed, but I'm pretty sure its $90M nominal valuation is mostly non-cash. I.e. the point of this reverse-merger is to pursue Cend's pipeline using CLBS' cash and Nasdaq listing.